777 related articles for article (PubMed ID: 25104775)
21. Complement factor B inhibitor LNP023 improves lupus nephritis in MRL/lpr mice.
Chen K; Deng Y; Shang S; Tang L; Li Q; Bai X; Chen X
Biomed Pharmacother; 2022 Sep; 153():113433. PubMed ID: 36076550
[TBL] [Abstract][Full Text] [Related]
22. Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis.
Knight JS; Luo W; O'Dell AA; Yalavarthi S; Zhao W; Subramanian V; Guo C; Grenn RC; Thompson PR; Eitzman DT; Kaplan MJ
Circ Res; 2014 Mar; 114(6):947-56. PubMed ID: 24425713
[TBL] [Abstract][Full Text] [Related]
23. Dichotomic effects of IFN-gamma on the development of systemic lupus erythematosus-like syndrome in MRL-lpr / lpr mice.
Nicoletti F; Di Marco R; Zaccone P; Xiang M; Magro G; Grasso S; Morrone S; Santoni A; Shoenfeld Y; Garotta G; Meroni P
Eur J Immunol; 2000 Feb; 30(2):438-47. PubMed ID: 10671199
[TBL] [Abstract][Full Text] [Related]
24. IL-10 regulates murine lupus.
Yin Z; Bahtiyar G; Zhang N; Liu L; Zhu P; Robert ME; McNiff J; Madaio MP; Craft J
J Immunol; 2002 Aug; 169(4):2148-55. PubMed ID: 12165544
[TBL] [Abstract][Full Text] [Related]
25. Y27, a novel derivative of 4-hydroxyquinoline-3-formamide, prevents the development of murine systemic lupus erythematosus-like diseases in MRL/lpr autoimmune mice and BDF1 hybrid mice.
Xiao ZY; Chen SH; Cheng JP; Zhou WX; Zhang YX; Yang RF; Yun LH
Arthritis Res Ther; 2012 Nov; 14(6):R235. PubMed ID: 23116248
[TBL] [Abstract][Full Text] [Related]
26. Siglec-G deficiency leads to more severe collagen-induced arthritis and earlier onset of lupus-like symptoms in MRL/lpr mice.
Bökers S; Urbat A; Daniel C; Amann K; Smith KG; Espéli M; Nitschke L
J Immunol; 2014 Apr; 192(7):2994-3002. PubMed ID: 24600033
[TBL] [Abstract][Full Text] [Related]
27. Interferon regulatory factor-5 deficiency ameliorates disease severity in the MRL/lpr mouse model of lupus in the absence of a mutation in DOCK2.
Yasuda K; Watkins AA; Kochar GS; Wilson GE; Laskow B; Richez C; Bonegio RG; Rifkin IR
PLoS One; 2014; 9(7):e103478. PubMed ID: 25076492
[TBL] [Abstract][Full Text] [Related]
28. Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog.
Choi JY; Gao W; Odegard J; Shiah HS; Kashgarian M; McNiff JM; Baker DC; Cheng YC; Craft J
Arthritis Rheum; 2006 Oct; 54(10):3277-83. PubMed ID: 17009262
[TBL] [Abstract][Full Text] [Related]
29. Decreased miR-4512 Levels in Monocytes and Macrophages of Individuals With Systemic Lupus Erythematosus Contribute to Innate Immune Activation and Neutrsophil NETosis by Targeting TLR4 and CXCL2.
Yang B; Huang X; Xu S; Li L; Wu W; Dai Y; Ge MX; Yuan L; Cao W; Yang M; Wu Y; Deng D
Front Immunol; 2021; 12():756825. PubMed ID: 34721432
[TBL] [Abstract][Full Text] [Related]
30. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
[TBL] [Abstract][Full Text] [Related]
31. Targeted tumor necrosis factor receptor I preligand assembly domain improves skin lesions in MRL/lpr mice.
Deng GM; Liu L; Tsokos GC
Arthritis Rheum; 2010 Aug; 62(8):2424-31. PubMed ID: 20506390
[TBL] [Abstract][Full Text] [Related]
32. Interferon regulatory factor 5 is critical for the development of lupus in MRL/lpr mice.
Tada Y; Kondo S; Aoki S; Koarada S; Inoue H; Suematsu R; Ohta A; Mak TW; Nagasawa K
Arthritis Rheum; 2011 Mar; 63(3):738-48. PubMed ID: 21305501
[TBL] [Abstract][Full Text] [Related]
33. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
34. Targeting peptidylarginine deiminase reduces neutrophil extracellular trap formation and tissue injury in severe acute pancreatitis.
Madhi R; Rahman M; Taha D; Mörgelin M; Thorlacius H
J Cell Physiol; 2019 Jul; 234(7):11850-11860. PubMed ID: 30515825
[TBL] [Abstract][Full Text] [Related]
35. Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus.
Shimp SK; Chafin CB; Regna NL; Hammond SE; Read MA; Caudell DL; Rylander M; Reilly CM
Cell Mol Immunol; 2012 May; 9(3):255-66. PubMed ID: 22543833
[TBL] [Abstract][Full Text] [Related]
36. Murine lupus is neutrophil elastase-independent in the MRL.Faslpr model.
Gordon RA; Tilstra JS; Marinov A; Nickerson KM; Bastacky SI; Shlomchik MJ
PLoS One; 2020; 15(4):e0226396. PubMed ID: 32243431
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of glutaminolysis ameliorates lupus by regulating T and B cell subsets and downregulating the mTOR/P70S6K/4EBP1 and NLRP3/caspase-1/IL-1β pathways in MRL/lpr mice.
Zhang X; Wang G; Bi Y; Jiang Z; Wang X
Int Immunopharmacol; 2022 Nov; 112():109133. PubMed ID: 36113317
[TBL] [Abstract][Full Text] [Related]
38. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF).
Zhou L; Sun L; Wu H; Zhang L; Chen M; Liu J; Zhong R
Eur J Pharmacol; 2013 Sep; 715(1-3):230-7. PubMed ID: 23712004
[TBL] [Abstract][Full Text] [Related]
39. Role of MHC-linked genes in autoantigen selection and renal disease in a murine model of systemic lupus erythematosus.
Sekine H; Graham KL; Zhao S; Elliott MK; Ruiz P; Utz PJ; Gilkeson GS
J Immunol; 2006 Nov; 177(10):7423-34. PubMed ID: 17082662
[TBL] [Abstract][Full Text] [Related]
40. Neuropsychiatric systemic lupus erythematosus persists despite attenuation of systemic disease in MRL/lpr mice.
Stock AD; Wen J; Doerner J; Herlitz LC; Gulinello M; Putterman C
J Neuroinflammation; 2015 Nov; 12():205. PubMed ID: 26546449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
